Navigating FDA's New Human Factors Guidance vs. EU MDR Usability Requirements

Introduction: Content of Human Factors Information in Medical Device Marketing Submissions

On May 29, 2026, FDA finalized "Content of Human Factors Information in Medical Device Marketing Submissions," giving manufacturers a clearer, risk-based roadmap for what usability information is compulsory in a 510(k), PMA, De Novo, or HDE submission.

Key Takeaways:

• Risk-Based Categorization: The FDA’s final guidance (issued May 29, 2026) establishes three clear "HF Submission Categories" based on a four-question decision tree, shifting the focus from automatic testing to a strategic evaluation of user interface risk.
• Justification vs. Testing: Under the new FDA framework, the presence of modified or complex user interfaces does not automatically trigger a full human factors validation study. With robust objective data and a clear use history, medical device startups and OEMs can submit a structured rationale instead.
• US vs. EU Divergence: While the FDA utilizes a tiered, submission-specific screening process, the EU MDR integrates usability uniformly across all risk classes via Annex I and EN IEC 62366-1, auditing documentation as a permanent part of the technical file.

The Roadmap

The roadmap utilizes a four-question decision tree that directs a submission into one of three "HF Submission Categories." Category 1 is the express lane, covering devices or modifications with no impact on the user interface, users, uses, environment, training, or labeling‚ requiring only a brief concluding statement before proceeding. Category 2 is a slower lane reserved for cases where critical tasks exist but aren't newly introduced or affected, calling for a documented rationale rather than a full pit stop for new testing. Category 3, the most demanding stretch of road, requires a full human factors validation study whenever critical tasks are newly created or meaningfully impacted and existing risk controls are no longer applicable or sufficient to keep things on course.

Helpfully, FDA's real-world worked examples cover everything from anesthesia gas machines to augmented-reality surgical navigation to pediatric glucose monitors‚ which illustrate how subtle interface changes (like swapping a physical knob for a touchscreen slider) can act as a detour, redirecting a submission onto an entirely different category. 

Submissions filed before August 1, 2026, enjoy a green light grace period, but going forward, this new framework aims to cut down review delays by front-loading targeted, risk-based usability evidence before manufacturers ever merge onto the submission highway.

How This Compares to the EU's Approach

The EU takes a structurally different route. Rather than a tiered submission-category system, MDR (Regulation 2017/745) folds usability into Annex I's General Safety and Performance Requirements, which apply uniformly to every device regardless of risk class; a long road, no exit ramps. Manufacturers demonstrate conformity primarily through EN IEC 62366-1, the usability engineering standard covering formative and summative evaluation, which Notified Bodies then audit as part of the technical file and design-control review.

The testing philosophy also diverges. FDA's guidance installs a clear traffic signal: validation testing is either required (Category 3, red light), justified via written rationale (Category 2, yellow light), or not applicable/required (Category 1, green light). IEC 62366-1 instead asks manufacturers to either test every hazard-related use scenario or justify a reasoned subset based on severity; serving more like a yield sign than a stoplight, leaving room for judgment rather than a hard categorical trigger. Additionally, the EU MDR does not specify a minimum number of test participants, whereas FDA guidance recommends around 15 users per distinct user group in summative testing.

Frequently Asked Questions

What is a Use-Related Risk Analysis (URRA)?

A Use-Related Risk Analysis (URRA) is a systematic compliance document that identifies potential user errors, the clinical consequences of those errors, and the specific user interface design controls implemented to mitigate those risks.

What constitutes a "critical task" under FDA usability engineering definitions? 

A critical task is a user action or omission that, if performed incorrectly, could result in serious harm to the patient or the medical device operator.

What does "Decision Point D" mean for modified medical devices?

Added in the final 2026 guidance, Decision Point D allows manufacturers to evaluate a device’s user interface history of safe use, design complexity, and existing risk mitigations. This means a device with a modified or complex interface does not automatically require new validation testing if current risk controls are proven effective.

Do I need to submit human factors data if my device is Category 1 or 2?

For Category 1, you only need to submit a high-level concluding statement. For Category 2, you must submit a well-supported, written rationale explaining why new testing isn't required. However, the FDA notes that all underlying human factors data and testing results must be maintained within your internal Quality Management System (QMS) for potential review during routine facility inspections.

How does Kapstone Medical support teams navigating these human factors frameworks?

As a single-source development partner, Kapstone Medical bridges engineering design, regulatory affairs, and quality systems under one roof. We help startups build the URRA directly into initial design controls to map hazards early, guide mid-stage developers through Category 2 screening justifications to save on clinical costs, and execute full Category 3 summative validation studies with the recommended 15 participants per user group.

Additional Resources

• Kapstone Medical Human Factors Engineering & Usability Services: Learn more about our comprehensive early-stage offerings on the Kapstone Medical Human Factors Engineering & Usability Page.
• U.S. Food and Drug Administration (FDA): Final Guidance: Content of Human Factors Information in Medical Device Marketing Submissions
• U.S. Food and Drug Administration (FDA): Applying Human Factors and Usability Engineering to Medical Devices
• European Commission: Medical Devices Regulation (EU) 2017/745 (MDR) Official Text